←
Dominik Paul Modest36 posts
Dominik Paul Modest avatar

Dominik Paul Modest

@ModestDominik
◷ Joined April 2021▧ 1 Photos and videos
NEJM avatar
⟳ Dominik Paul Modest retweeted
NEJM@NEJM·23 Oct 2023

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) nej.md/3M8Qw3k #ESMO23 #oncology

Post attachment
GI CONNECT powered by COR2ED avatar
⟳ Dominik Paul Modest retweeted
GI CONNECT powered by COR2ED@giconnectInfo·6 Oct 2022

Five @giconnectInfo experts provide a handy update from #ESMO2022! ➡️ Podcast Ep. 1: Lower #GIcancer highlights ➡️ Podcast Ep. 2: Upper #GIcancer highlights ➡️ Video summary of NICHE-2 trial For the podcasts, video and downloadable content, follow: ow.ly/6GQF50L2EhI #MedEd

Jenny Seligmann avatar
⟳ Dominik Paul Modest retweeted
Jenny Seligmann@JenSeligmann·11 Sep 2022

💥💥💥💥@MyriamChalabi #ESMO22 discussing NICHE2 - neoadjuvant nivo/ipi in locally advanced colon cancer 💥short duration safe pre-op 💥4% grade 3 events 💥100% R0 resection 💥95% major path; 67% pCR …round of applause in session! 1/2

Post attachmentPost attachmentPost attachment
Dominik Paul Modest avatar
Dominik Paul Modest@ModestDominik·11 Sep 2022

Niche-2. No need for further interpretation… congrats to Myriam!! What a perfect presentation of a super trial. Great that we had a wowww moment in colon cancer.

Post attachment
Dominik Paul Modest avatar
Dominik Paul Modest@ModestDominik·11 Sep 2022

Great to see randomized data. Congratulations!! Great achievement. Final conclusion (do it or not) more complex. Data suggest that HIPEC influences local but not systemic control and systemic relapse is a frequent issue.

HIPECT4 shows that HIPEC with MMC in effective and safe to prevent peritoneal relapse in T4 colorectal cancer, presented in @myESMO 2022. @AndreaCercek @PSOGI_EC @ESSOnews @aecirujanos @_SEOM @indepso @ISSPP1 @HUReinaSofia @IMIBIC @SeguraJuanJ @operarelcancer @GECOP_ @PSugarbaker

Post attachmentPost attachmentPost attachmentPost attachment
Nathanael Raschzok avatar
⟳ Dominik Paul Modest retweeted
Nathanael Raschzok@nathanaelraschz·5 Apr 2022

The protocol of the PORT trial is published, which aims to generate evidence that post-resection/ablation/radiation chemotherapy improves the survival in patients with metastatic colorectal cancer. bmccancer.biomedcentral.com/… @ModestDominik @Sauer_et_al

Charité - Universitätsmedizin Berlin avatar
⟳ Dominik Paul Modest retweeted
Charité - Universitätsmedizin Berlin@ChariteBerlin·21 Oct 2021

Eine interdisziplinäre klinische Studie zur Therapie von #Darmkrebs startet nun unter Leitung der #CharitéBerlin. Die FIRE-9/PORT-Studie soll helfen, die Neuentstehung von Metastasen zu verhindern. @ModestDominik @StintzingS @AIO_Onkologie @LMU_Uniklinikum charite.de/service/pressemit…